• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488).

作者信息

Mahé E, Geldhof A, Jazra M, Bergmans P, Azzabi A, Seyger M M B

机构信息

Department of Dermatology, Centre Hospitalier Victor Dupouy, Argenteuil, France.

Medical Affairs, Janssen Biologics BV, Leiden, Netherlands.

出版信息

J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e646-e648. doi: 10.1111/jdv.18110. Epub 2022 Apr 6.

DOI:10.1111/jdv.18110
PMID:35349743
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10286644/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/007a/10286644/dd65b4a5634c/JDV-36-e646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/007a/10286644/dd65b4a5634c/JDV-36-e646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/007a/10286644/dd65b4a5634c/JDV-36-e646-g001.jpg

相似文献

1
Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488).优特克单抗在中度至重度斑块状银屑病青少年患者中的安全性：一项正在进行的欧洲研究（NCT03218488）的真实世界证据
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e646-e648. doi: 10.1111/jdv.18110. Epub 2022 Apr 6.
2
Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.瑞莎珠单抗与优特克单抗治疗中度至重度斑块状银屑病的对比
Dermatol Ther. 2017 Sep;30(5). doi: 10.1111/dth.12507. Epub 2017 May 16.
3
Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.生物制剂优特克单抗、司库奇尤单抗和依奇珠单抗治疗斑块状银屑病的12周疗效和安全性比较：一项真实世界多中心回顾性研究。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e416-e418. doi: 10.1111/jdv.16366. Epub 2020 May 8.
4
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.在中重度斑块型银屑病中的疗效和安全性（UltIMMa-1 和 UltIMMa-2）：两项双盲、随机、安慰剂对照和乌司奴单抗对照的 3 期临床试验结果。
Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.
5
An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.乌司奴单抗治疗中重度银屑病的药物生存、有效性及安全性分析：一项针对69例常规临床实践患者的观察性研究
Actas Dermosifiliogr (Engl Ed). 2019 Apr;110(3):244-246. doi: 10.1016/j.ad.2018.02.019. Epub 2018 Jun 28.
6
Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.治疗一年后，中度至重度银屑病患者使用司库奇尤单抗与优特克单抗实现皮肤清除的对比：真实世界实践
Dermatol Ther. 2020 Nov;33(6):e14202. doi: 10.1111/dth.14202. Epub 2020 Sep 7.
7
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.司库奇尤单抗在清除中重度斑块型银屑病患者皮肤方面优于乌司奴单抗：来自 CLEAR 研究的结果。
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20.
8
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.接受ixekizumab、etanercept和ustekinumab治疗的中重度银屑病患者治疗中出现的湿疹样反应的综合安全性分析。
Br J Dermatol. 2021 Oct;185(4):865-867. doi: 10.1111/bjd.20527. Epub 2021 Aug 10.
9
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.司库奇尤单抗在清除亚洲中重度斑块型银屑病患者的皮肤方面优于乌司奴单抗：来自 CLEAR 研究的亚组分析。
J Dermatol. 2019 Sep;46(9):752-758. doi: 10.1111/1346-8138.15004. Epub 2019 Jul 25.
10
Severe disseminated Nocardia infection associated with ustekinumab treatment for psoriasis.与乌司奴单抗治疗银屑病相关的严重播散性诺卡菌感染
Br J Dermatol. 2019 Jul;181(1):194-195. doi: 10.1111/bjd.17642. Epub 2019 Feb 27.

引用本文的文献

1
A complex case of acute abdomen.一例复杂的急腹症病例。
Int J Emerg Med. 2025 Aug 11;18(1):150. doi: 10.1186/s12245-025-00954-9.

本文引用的文献

1
Impact of the COVID-19 pandemic on children with psoriasis.2019年冠状病毒病大流行对银屑病患儿的影响。
Ann Dermatol Venereol. 2021 Jun;148(2):106-111. doi: 10.1016/j.annder.2021.01.005. Epub 2021 Feb 23.
2
A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.甲氨蝶呤与生物制剂治疗儿童银屑病患者的严重程度比较。
JAMA Dermatol. 2020 Apr 1;156(4):384-392. doi: 10.1001/jamadermatol.2019.4835.
3
Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
儿童银屑病的生物治疗：一项回顾性观察研究，评估生物药物在儿童银屑病日常治疗中的生存情况。
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1984-1992. doi: 10.1111/jdv.15579. Epub 2019 Apr 15.
4
Treatment of severe psoriasis in children: recommendations of an Italian expert group.儿童重度银屑病治疗：意大利专家组建议。
Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.
5
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.乌司奴单抗治疗 12 至 17 岁中重度斑块状银屑病青少年患者的随机 3 期 CADMUS 研究结果。
J Am Acad Dermatol. 2015 Oct;73(4):594-603. doi: 10.1016/j.jaad.2015.07.002. Epub 2015 Aug 7.
6
Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities.儿童和青少年银屑病：诊断、管理及合并症
Paediatr Drugs. 2015 Oct;17(5):373-84. doi: 10.1007/s40272-015-0137-1.